Europe

September 22, 2020September 22, 2020

Lynparza’s Approval Favored in EU for mCRPC Patients with BRCA Mutations

News

Lynparza (olaparib) has been recommended for approval in the European Union to treat men with metastatic castration-resistant prostate cancer (mCRPC) who carry mutations in BRCA1 and BRCA2, two DNA repair genes. The marketing authorization application ... Read more

January 29, 2020January 30, 2020

Erleada Approved in Europe to Treat Metastatic Hormone-sensitive Prostate Cancer

News

The European Commission (EC) has agreed to extend the use of Janssen’s Erleada (apalutamide) to treat men whose metastatic prostate cancer still responds to androgen deprivation therapy (ADT), a condition known ... Read more

January 6, 2020January 30, 2020

EMA Committee Favors Extending Use of Erleada for Metastatic Castration-sensitive Prostate Cancer

News

The Committee for Medicinal Products for Human Use recommends extending the use of Janssen’s Erleada (apalutamide), in combination with androgen deprivation therapy (ADT), to treat men with metastatic hormone-sensitive prostate cancer ... Read more

November 10, 2014November 10, 2014

Optical Diagnostic Device Can Diagnose Prostate Cancer in Minutes

News

Eager attendees of the upcoming COMPAMED trade fair in Düsseldorf this week, Wednesday, November 12 – 14, will have an opportunity to witness a demonstration of a groundbreaking medical device ... Read more